Clinical Trial Update: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on recombinant human C1 inhibitor (Ruconest) for acute attacks in hereditary angioedema, covering Phase 2/3 studies with the trial status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Ruconest (conestat alfa)

Snippet

Sponsor: Pharming Technologies B.V. | Conditions: Genetic Disorders | Phase 2, Phase 3 | Status: COMPLETED